• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:陈文霖,刘笑静.化痰止咳合剂对AECOPD患者血清SAA、IL-6、IL-1β和肺功能的影响[J].中国现代应用药学,2017,34(3):432-435.
Chen Wenlin,Liu Xiaojing.Clinical Study on the Effects of Huatan Zhike Mixture on the levels of Serum SAA, IL-6, IL-1β and Lung Function in Acute Exacerbated Chronic Obstructive Pulmonary Disease Patients[J].Chin J Mod Appl Pharm(中国现代应用药学),2017,34(3):432-435.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1888次   下载 1409 本文二维码信息
码上扫一扫!
分享到: 微信 更多
化痰止咳合剂对AECOPD患者血清SAA、IL-6、IL-1β和肺功能的影响
陈文霖, 刘笑静
丽水市中医院, 浙江 丽水 323000
摘要:
目的 研究化痰止咳合剂对慢性阻塞性肺疾病急性加重(acute exacerbations chronic obstructive pulmonary disease,AECOPD)患者血清淀粉样蛋白A(SAA)、白介素-6(IL-6)、白细胞介素-1β(IL-1β)和肺功能的影响。方法 将60例AECOPD患者按随机数字表法分为治疗组30例与对照组30例,2组均予常规治疗,治疗组在此基础上加用化痰止咳合剂30 ml,每日3次,共14 d,2组均在治疗前后检测血清SAA、IL-1β、IL-6、第1秒用力呼气量/用力肺活量(FEV1/FVC)、FEV1占预计值百分比(FEV1%),采用临床COPD问卷(clinical COPD questionnaire,CCQ)调查临床症状改善情况。结果 治疗前2组患者血清清SAA、IL-1β、IL-6、FEV1/FVC及FEV1%、CCQ评分分值均无统计学差异(P>0.05);治疗后,与治疗前比较,2组患者血清SAA、IL-6、IL-1β、肺功能、CCQ评分值有统计学意义(P<0.05);与对照组比较,治疗组血清SAA、IL-6、IL-1β、CCQ评分值差异有统计学意义(P<0.05),2组FEV1/FVC、FEV1%差异无统计学意义(P>0.05)。结论 化痰止咳合剂临床疗效确切,可抑制SAA、IL-6、IL-1β水平及改善患者临床症状,其作用机制可能与其通过调节上述炎症因子的表达而发挥降低气道炎症反应作用有关。
关键词:  慢性阻塞性肺疾病急性加重  化痰止咳合剂  血清淀粉样蛋白A  白介素-6  白介素-1β  肺功能
DOI:10.13748/j.cnki.issn1007-7693.2017.03.030
分类号:
基金项目:
Clinical Study on the Effects of Huatan Zhike Mixture on the levels of Serum SAA, IL-6, IL-1β and Lung Function in Acute Exacerbated Chronic Obstructive Pulmonary Disease Patients
Chen Wenlin, Liu Xiaojing
Traditional Chinese Medical Hospital of Lishui, Lishui 323000, China
Abstract:
OBJECTIVE To investigate the effect of Huatan Zhike mixture on the levels of serum SAA, IL-6, IL-1β and lung function in acute exacerbated chronic obstructive pulmonary disease(AECOPD) patients. METHODS Sixty patients with AECOPD were randomly assigned to the treatment group and the control group. All the patients were treated with routine western medical therapy and the patients in the treatment group were added with Huatan Zhike mixuture orally, with a course of 14 days. The changes of SAA, IL-6, IL-1β, the pulmonary functions and CCQ scores were evaluated before treatment and after treatment. RESULTS before treatment, there were no significant differences in the value of SAA, IL-6, IL-1β, FEV1/FVC and FEV1% between two group(P>0.05). After treatment, the levels of serum SAA, IL-6, IL-1β and CCQ scores were significantly lower than that before treatment(P<0.05); compared with the control group, the levels of serum SAA, L-6, IL-1β and CCQ scores in treatment group were decreased significantly(P<0.05); there were no significant differences between two group in the levels of FEV1% and FEV1/FVC. CONCLUSION Huatan Zhike mixture can reduce the levels of SAA, IL-6 and IL-1β, and improve the clinical symptoms in AECOPD patients. The mechanisms may be related to certain anti-inflammatory effects on improve clinical efficacy of AECOPD patients..
Key words:  AECOPD  Huatan Zhike mixture  SAA  IL-6  IL-1β  lung function
扫一扫关注本刊微信